BRCA2 and cancer: Studies have shown that hypoxia-induced by anti-angiogenic therapy inhibits HR repair by suppressing the expression of key factors such as BRCA1 and BRCA2, leading to a deficiency in DDR and rendering BRCA1/2 wild-type cancer cells sensitive to PARPi (107, 108).